Ulland Investment Advisors’s AbbVie ABBV Stock Holding History

Ulland Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-150	Closed	-$30K	–	209
2024 Q3	$30K	Hold	150	–	–	0.02%	124
2024 Q2	$26K	Hold	150	–	–	0.02%	132
2024 Q1	$27K	Hold	150	–	–	0.02%	134
2023 Q4	$23K	Hold	150	–	–	0.02%	130
2023 Q3	$22K	Hold	150	–	–	0.02%	134
2023 Q2	$20K	Hold	150	–	–	0.02%	138
2023 Q1	$24K	Hold	150	–	–	0.03%	119
2022 Q4	$24K	Hold	150	–	–	0.03%	121
2022 Q3	$20K	Hold	150	–	–	0.02%	131
2022 Q2	$23K	Hold	150	–	–	0.02%	134
2022 Q1	$24K	Hold	150	–	–	0.02%	143
2021 Q4	$20K	Buy	+150	New	+$17.7K	0.01%	145

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Ulland Investment Advisors's ABBV Position: Q4 2024 in Review

Ulland Investment Advisors sold out of AbbVie (ABBV) in Q4 2024, closing a stake of 150 shares — an estimated $30K sold.

Ulland Investment Advisors first reported a position in ABBV in Q4 2021 and held it in 12 quarters. The position peaked at $30K in Q3 2024. 3,744 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

Ulland Investment Advisors reported no remaining AbbVie position as of Q4 2024 after selling out during the quarter.
Ulland Investment Advisors sold 150 AbbVie shares in Q4 2024, an estimated $30K.
Ulland Investment Advisors first reported a position in AbbVie in Q4 2021 and held it in 12 quarters.
Ulland Investment Advisors's AbbVie position peaked at $30K in Q3 2024.
3,744 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Ulland Investment Advisors's 13F filing for Q4 2024, filed 16 Jan 2025.